Advertisement
Table 1 Clinical and biochemical characteristics of 20 patients with type 2 diabetes at baseline and after 4 months of nateglinide or rosiglitazone therapy
| Variables | Baseline | Nateglinide | p | Baseline | Rosiglitazone | p | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| After 4 months | After 4 months | |||||||||
| Median | (25th–75th) | Median | (25th–75th) | Median | (25th–75th) | Median | (25th–75th) | |||
| Body weight (kg) | 67.9 | (64.1–81.0) | 70.0 | (64.5–78.0) | 0.073 | 69.0 | (63.9–77.0) | 68.9 | 63.6–77.9 | 0.984 |
| Hba1c (%) | 7.45 | (7.0–8.3) | 6.65 | (5.7–7.8) | 0.032 | 7.2 | (6.8–8.1) | 6.6 | 5.5–7.5 | 0.036 |
| Homa Beta | 40.7 | (28.8–52.0) | 51.3 | (28.7–73.0) | 0.126 | 33.6 | (26.8–59.0) | 51.6 | 30.9–69.9 | 0.005 |
| Total-c (mg/dL) | 223.5 | (178.5–235.3) | 194.0 | (182.0–213.0) | 0.036 | 213.0 | (184.0–230.0) | 211.0 | 201.0–245.0 | 0.277 |
| HDL-c (mg/dL) | 44.5 | (37.8–57–8) | 44.5 | (34.0–55.0) | 0.360 | 45.0 | (40.0–56.0) | 48.0 | 38.0–55.0 | 0.347 |
| LDL-c (mg/dL) | 144.0 | (111.0–153.5) | 131.5 | (109.5–142.0) | 0.145 | 152.0 | (106.0–157.0) | 142.0 | 124.0–168.0 | 0.355 |
| CRP (mg/L) | 5.2 | (1.87–8.91) | 3.79 | (1.63–7.64) | 0.052 | 4.16 | (2.23–8.37) | 3.10 | (0.87–6.34) | 0.042 |
| TGF β (pg/mL) | 44.1 | (34.2–51.1) | 45.3 | (32.2–49.4) | 0.247 | 42.7 | (37.8–47.9) | 38.3 | 32.0–45.8 | 0.001 |
| Interleukin-6 (pg/mL) | 2.54 | (1.45–5.66) | 2.37 | (1.16–3.53) | 0.108 | 2.71 | (1.46–4.17) | 2.00 | 1.42–3.89 | 0.520 |
| leptina (ng/mL) | 14.9 | (7.6–21.0) | 17.9 | (10.0–20.8) | 0.808 | 13.1 | (6.0–19.3) | 16.2 | 7.0–24.1 | 0.199 |
| sICAM-1 (ng/mL) | 233.8 | (179.7–261.5) | 214.9 | (186.7–263.3) | 0.391 | 223.6 | (171.3–241.6) | 218.0 | 173.8–246.0 | 0.573 |
| TNF α (pg/mL) | 1.71 | (1.18–2.50) | 1.52 | (1.08–2.91) | 0.235 | 1.49 | (1.23–2.09) | 1.43 | 1.18–2.18 | 0.760 |
| fibrinogen (mg/dL) | 316.0 | (276.8–375.0) | 336.5 | (297.8–357–5) | 0.433 | 337.0 | (296–397) | 322.0 | (262.5–363.8) | 0.024 |
| PA-1 activity (UI/mL) | 27.7 | (14.4–43.8) | 24.7 | (14.7–40.3) | 0.55 | 15.9 | (11.6–40.0) | 12.7 | 8.0–19.0 | 0.040 |
| platelet aggregation | 90.3 | (80.1–96.0) | 90.0 | (81.0–92.6) | 0.601 | 89.0 | (76.4–94.5) | 90.9 | 76.0–95.0 | 0.643 |
